EverHint Lens - Tango Therapeutics, Inc. (TNGX) - Yahoo Finance Top Gainer Stock Analysis - March 05, 2026

Analysis Date : 2026-03-05
Sector : Healthcare
Industry : Biotechnology
Exchange : NASDAQ

Executive Summary

Tango Therapeutics, Inc. is currently trading at $15.80 (🟢 +27.94% today) with a market capitalization of $1.75B.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.

Price & Valuation

Current Price : $15.80 (at 11:42 AM ET)
Current Volume : 6.2M
Day Range : $11.80 - $15.88
52-Week Range : $1.03 - $15.88
P/E Ratio : N/A

DCF Valuation : Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-03-05.

Market Context

Healthcare Sector : -1.33497% | Sector P/E : 32.51

Major Indices :

S&P 500: $6817.16 (🔴 -0.76%)
NASDAQ Composite: $22708.92 (🔴 -0.43%)
Dow Jones Industrial Average: $47939.36 (🔴 -1.64%)

Peer Comparison

Peer comparison (11 companies):

TNGX - Tango Therapeutics, Inc. ($15.80, +27.9%, $1.75B) ← Current
EYPT - EyePoint Pharmaceuticals, Inc. ($16.32, -9.3%, $1.35B)
KOD - Kodiak Sciences Inc. ($25.40, -5.4%, $1.34B)
NRIX - Nurix Therapeutics, Inc. ($15.41, -5.3%, $1.34B)
SEPN - Septerna, Inc. ($26.10, -9.5%, $1.17B)
BCAX - Bicara Therapeutics Inc. Common Stock ($18.61, +0.4%, $1.02B)
FTRE - Fortrea Holdings Inc. ($10.21, -1.6%, $944M)
URGN - UroGen Pharma Ltd. ($19.69, -2.3%, $922M)
XNCR - Xencor, Inc. ($11.35, -10.9%, $811M)
KURA - Kura Oncology, Inc. ($8.24, -3.6%, $717M)
PROK - ProKidney Corp. ($2.40, -2.6%, $674M)

Financial Performance

Latest Quarter (2025-12-31):

Revenue : $0.00M
Net Income : $-38.75M
EPS : $-0.30
Revenue Growth (QoQ) : -100.0%

Earnings Calendar

Next Earnings Report : 2026-05-11 (Before Market Open)

Most Recent Report : 2026-03-05

EPS: $-0.33 (Est: $-0.31) ✗ Miss

Historical Data : 25 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus :

Target : $15.00 (-5.1% upside)
Range : $12.00 - $19.00
Median : $14.50

Next Quarter Estimates (2027-12-30):

Revenue: $101.02M
EPS: $-0.41

Analyst Consensus

Overall Rating : Buy

Rating Distribution (27 total ratings):

🟢 Buy/Outperform : 27 (100.0%)
⚪ Hold/Neutral : 0 (0.0%)
🔴 Sell/Underperform : 0 (0.0%)

Recent Analyst Actions :

Guggenheim (2026-02-06): Maintained Buy
Piper Sandler (2026-01-16): Maintained Overweight
B. Riley Securities (2025-11-18): Maintained Buy
Guggenheim (2025-10-24): Maintained Buy
Guggenheim (2025-08-06): Maintained Buy

Consensus based on 27 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 5 trading signal(s) in the last 60 days:

2026-02-23 : Momentum Swing - breakout @ $12.73
2026-01-09 : Dip Bounce V2 Reclaim - RECLAIM_LONG @ $11.75
2026-01-07 : Dip Bounce V2 Reclaim - RECLAIM_LONG @ $11.79
2026-01-07 : Ema10 Ema30 - EMA10_x_EMA30_Buy @ $11.79
2026-01-06 : Dip Bounce V2 Reclaim - RECLAIM_LONG @ $9.67

Insider Activity

Recent Transactions (Last 10):

Buys: 5
Sells: 5

Notable Transactions :

2026-02-25: Crystal Adam - Sell (Sale, 54,345 shares @ $12.77)
2026-02-02: Beckman Daniella - Buy (Award, 265,980 shares @ $11.94)
2026-02-02: Beckman Daniella - Buy (Award, 44,330 shares)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Overall sentiment for Tango Therapeutics (TNGX) is positive, fueled by strong clinical data from vopimetostat trials showing promising PFS and ORR, substantial $225M financing, and analyst upgrades with significant upside targets. Recent institutional buying and stock reaching 52-week highs further bolster optimism, despite isolated insider selling and a Q2 revenue dip. Conference participations and CEO transitions highlight ongoing momentum in precision oncology.

Key Themes :

Clinical Progress
Analyst Optimism
Investor Activity

Sentiment : Positive (92% confidence)